Selank: Tuftsin Analog Heptapeptide — GABAergic Modulation & Anxiolytic Biology Research

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, constituting a modified analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with a C-terminal Pro-Gly-Pro extension. The compound was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, where the same research group responsible for Semax recognized that appending the Pro-Gly-Pro sequence to biologically active neuropeptides significantly extended their in vivo half-life by protecting against enzymatic degradation by prolyl endopeptidase and carboxypeptidases.

Tuftsin itself is an endogenous immunomodulatory tetrapeptide derived from the Fc region of IgG, known for its phagocytosis-stimulating activity on macrophages and neutrophils. Selank diverges from tuftsin's immunological research context to exhibit a distinct profile of central nervous system activities in preclinical research, including GABAergic interactions, enkephalin degradation inhibition, and cytokine modulation — making it a multi-target research tool for studying the intersection of immune-neuro signaling pathways.

Biochemical Identity & Structural Properties

Proposed Mechanisms of Action

GABA-A Receptor Allosteric Modulation

Research has examined Selank's effects on GABAergic neurotransmission, documenting interactions consistent with positive allosteric modulation of GABA-A receptors in neuronal cell culture preparations and ex vivo brain tissue assays. Studies have characterized Selank's effects on chloride ion flux in patched neurons, with data indicating modulation of GABA-A receptor subunit expression profiles in rodent brain tissue following repeated administration. This pharmacological profile — sharing characteristics with benzodiazepine-class positive allosteric modulators without direct binding at the classical benzodiazepine site — has made Selank a research tool for studying alternative GABAergic modulatory mechanisms in anxiety biology paradigms.

Enkephalin Degradation Inhibition

A mechanistically distinct property of Selank documented in published research is its inhibition of enkephalin-degrading enzymes, particularly neprilysin (neutral endopeptidase, NEP) and dipeptidyl peptidase IV (DPP-IV). Zozulya et al. characterized enkephalinase inhibition as a primary molecular mechanism by which Selank increases the half-life of endogenous Met-enkephalin and Leu-enkephalin in brain tissue preparations — connecting the peptide's anxiolytic activity profile in behavioral assays to opioid peptide system biology. This dual mechanism (GABAergic modulation + enkephalin stabilization) positions Selank as a multi-target research probe for studying interactions between GABAergic and opioidergic systems.

Cytokine Modulation — IL-6 and Interferon Research

As a tuftsin derivative, Selank retains interactions with immune cell populations, and research has documented modulation of cytokine secretion profiles in peripheral blood mononuclear cell cultures. Published studies have examined Selank's effects on IL-6, IFN-γ, and IL-10 secretion in stimulated PBMC preparations, generating data on how a GABAergic neuropeptide influences immune cytokine balance — a research question relevant to neuroimmunology and stress-immunology research programs. Studies have also examined Selank's effects on the IL-6/STAT3 signaling axis in neural cell preparations, exploring potential neuro-immune crosstalk mechanisms.

Summary of Published Research Findings

• Anxiolytic-like behavior in rodent paradigms: Behavioral pharmacology studies using the elevated plus maze, open field test, and Vogel conflict test paradigms documented anxiolytic-profile effects in rodents following Selank administration, with effect magnitudes compared to diazepam at equivalent behavioral doses in published studies.
• Absence of benzodiazepine-type side effects in animal models: Published research examined muscle relaxation, motor coordination (rotarod test), and sedation endpoints in rodent models, documenting that Selank at anxiolytic doses did not impair motor function — distinguishing its profile from classical benzodiazepine reference compounds in these paradigms.
• Monoamine system interactions: Brain microdialysis studies have examined changes in serotonin and dopamine release in prefrontal cortex and hippocampus preparations following Selank, providing data on monoaminergic system involvement in the compound's behavioral activity profile.
• BDNF modulation: Studies in stressed rodent models have documented that Selank administration prevented the stress-associated decline in hippocampal BDNF mRNA observed in control stressed animals, connecting Selank's research profile to the neurotrophin biology field.

Key Published References

Zozulya AA, Nezavibathko VN, Semenova TP, et al. (1999). Synthetic tetrapeptide Selank and its analog selank-amide: Effects on memory and anxiety in rats. Zhurnal Vysshei Nervnoi Deyatelnosti Imeni I P Pavlova, 49(3), 459–467. PMID: 10459655

Semenova TP, Kozlovskii II, Zakharova NM, Kozlovskaia MM. (2010). [Experimental optimization of learning and memory processes by selank]. Eksperimental'naia i Klinicheskaia Farmakologiia, 73(8), 2–5. PMID: 20949793

Pavlov TS, Gritsenko DA, Lavrova EA, et al. (2015). The anxiolytic peptide selank inhibits enkephalin-degrading enzymes in vitro. Doklady Biochemistry and Biophysics, 460(1), 23–25. PMID: 25726729

Storage & Laboratory Handling

• Lyophilized powder: −20°C in desiccated, light-protected conditions. Stable for 24+ months.
• Reconstitution: Dissolve in sterile saline or PBS. The heptapeptide is hydrophilic and does not require organic solvent co-solvents.
• Working solutions: Store at 4°C; use within 7 days. Single-use aliquots recommended to avoid freeze-thaw degradation. No cysteine residues — no disulfide bond concerns.